Results 121 to 130 of about 516,619 (288)

New bispecific antibodies in diffuse large B-cell lymphoma

Haematologica
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Adrian G. Minson, Michael J. Dickinson
doaj   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein

, 2021
BACKGROUND: Alzheimer’s disease (AD) and other tauopathies are neurodegenerative disorders characterized by cellular accumulation of aggregated tau protein.
Löffler, T, Schöll, M, Vogels, T, Burmann, BM, Quint, WH, Schilcher, I, Matečko-Burmann, I   +6 more
core  

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

A Rare Case of Acquired Haemophilia A Following Sigmoid Adenocarcinoma: Case Report and Literature Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Acquired haemophilia A (AHA) is a rare complication of malignancy. We report a case of AHA secondary to colorectal cancer which presented as post‐operative bleeding, progressive activated partial thromboplastin time prolongation, precipitous factor VIII (FVIII) decline and inhibitor development.
Benjamin Reardon, Harini Haran, Jennifer Curnow   +2 more
wiley   +1 more source

The evolution of bispecific antibodies [PDF]

Expert Opinion on Biological Therapy, 2022
openaire   +2 more sources

Multivalent and bispecific immunostimulatory antibodies for cancer immunotherapy

Immunostimulatory antibodies (ISAs) targeting TNFRSF members have shown anti-tumour efficacy in pre-clinical cancer models, but this has not translated into clinical success, primarily due to lack of efficacy and dose-limiting toxicity.
Widdess, Marcus Alexander
core   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau, Déborah Harboun, Pierre‐Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, Benjamin Wolff, Héloïse Torres‐Villaros, Audrey Giocanti‐Auregan, Mark Gillies, Catherine Creuzot–Garcher, Vincent Daien   +11 more
wiley   +1 more source